Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06176261 · ClinicalTrials.gov registry record · Phase 2

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

A Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, sponsored by Sarah Sammons, MD.

Recruiting
Registry status
Phase 2
Development phase
58
Enrollment target
3
Study locations

NCT06176261 is a Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer that is actively recruiting participants, run by Sarah Sammons, MD. The registered enrollment target is 58 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06176261, a Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by Sarah Sammons, MD.

RECRUITING
Registry status
Phase 2
Development phase
58 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)

Conditions Studied

Breast Cancer HER2-Negative Breast Cancer Breast Cancer Female Metastatic Triple-Negative Breast Carcinoma HER2-Negative Breast Carcinoma ER Positive Breast Cancer ER-negative Breast Cancer

Interventions

  • DRUG Datopotamab Deruxtecan

Study Locations (3)

Florida

  • Miami Baptist Cancer Institute/ - Miami

Massachusetts

  • Dana-Farber Cancer Institute - Boston

North Carolina

  • Duke University Medical Center - Durham

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2024-01-08
Est. Completion 2029-01-01
Phase Phase 2

Sponsor

Sarah Sammons, MD

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06176261

The ClinicalTrials.gov registry entry for NCT06176261 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Sarah Sammons, MD, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Datopotamab Deruxtecan is the first listed.

NCT06176261 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06176261 about?

NCT06176261 is a clinical study titled "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs". The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugat...

What is the current status of trial NCT06176261?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2024-01-08. Estimated completion is 2029-01-01.

What conditions does trial NCT06176261 study?

This clinical trial studies the following conditions: Breast Cancer, HER2-Negative Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, HER2-Negative Breast Carcinoma.

What interventions are being tested in trial NCT06176261?

The interventions under investigation include: Datopotamab Deruxtecan (DRUG).

Who is sponsoring clinical trial NCT06176261?

This trial is sponsored by Sarah Sammons, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06176261 being conducted?

This trial has 3 study locations across Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

HER2-Negative Breast Cancer

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.